Nakamura N, Miyazaki K, Kitano Y, Fujisaki S, Okamura H
Department of Obstetrics and Gynecology, Kumamoto University School of Medicine, Japan.
J Reprod Immunol. 1993 Mar;23(2):119-30. doi: 10.1016/0165-0378(93)90002-y.
We have investigated alterations in Epstein-Barr virus antigen specific cytotoxic T-lymphocyte (EBV-CTL) activity during human pregnancy. EBV-CTL activity was determined by a modified EBV induced B-cell focus regression assay and was expressed in terms of a regression index (IR50), i.e. the initial cell concentration required to achieve a 50%-incidence of regression in EBV-infected cell culture. Increased values of IR50 indicate the suppression of EBV-CTL activity. In 113 human female T-cell leukemia type-I (HTLV-I) non-carriers, the IR50 values (mean +/- S.E.) in non-pregnant, pregnant (the first trimester, second trimester and third trimester of pregnancy) and puerperal women were 10.6 +/- 1.4, 16.1 +/- 1.1 (20.1 +/- 2.0, 14.8 +/- 2.0, 14.6 +/- 1.6), and 12.1 +/- 1.9 respectively. Among HTLV-I carriers, the IR50 values (mean +/- S.E.) were likewise 34.6 +/- 8.0, 87.4 +/- 5.2 (101.7 +/- 6.3, 88.3 +/- 8.4 and 79.5 +/- 9.2) and 39.2 +/- 7.1 respectively. This data demonstrate: 1) EBV-CTL activity was suppressed during pregnancy (P < 0.05), especially in the first trimester (P = 0.0003). 2). In HTLV-I carriers, this suppression was shown in the first trimester (P = 0.0002), in the second trimester (P = 0.0002) and in the third trimester of pregnancy (P = 0.0014) and 3). One month after delivery, this suppression had returned to the non-pregnant level in both HTLV-I non-carriers and HTLV-I carriers. Pregnancy therefore has a suppressive effect on antigen specific cytotoxic T-lymphocyte activity and this effect is amplified in HTLV-I carriers.
我们研究了人类妊娠期间爱泼斯坦 - 巴尔病毒抗原特异性细胞毒性T淋巴细胞（EBV - CTL）活性的变化。EBV - CTL活性通过改良的EBV诱导B细胞集落消退试验测定，并以消退指数（IR50）表示，即EBV感染细胞培养中达到50%集落消退发生率所需的初始细胞浓度。IR50值增加表明EBV - CTL活性受到抑制。在113名I型人类T细胞白血病（HTLV - I）非携带者中，非孕妇、孕妇（妊娠早期、中期和晚期）及产后妇女的IR50值（均值±标准误）分别为10.6±1.4、16.1±1.1（20.1±2.0、14.8±2.0、14.6±1.6）和12.1±1.9。在HTLV - I携带者中，IR50值（均值±标准误）同样分别为34.6±8.0、87.4±5.2（101.7±6.3、88.3±8.4和79.5±9.2）和39.2±7.1。这些数据表明：1）妊娠期间EBV - CTL活性受到抑制（P < 0.05），尤其是在妊娠早期（P = 0.0003）。2）在HTLV - I携带者中，这种抑制在妊娠早期（P = 0.0002）、中期（P = 0.0002）和晚期（P = 0.0014）均有表现。3）分娩后一个月，HTLV - I非携带者和HTLV - I携带者的这种抑制均恢复到非妊娠水平。因此，妊娠对抗原特异性细胞毒性T淋巴细胞活性有抑制作用，且这种作用在HTLV - I携带者中会增强。
